top of page

ROSHER

REAL-WORLD DATA OF CLINICOPATHOLOGICAL CHARACTERISTICS AND MANAGEMENT OF PATIENTS WITH HER2+ BREAST CANCER (ROSHER).

BREAST

10

2000 (N1), 30000 (N2)

N/A

Spain

Closing

CLINICAL TRIAL DETAILS

THIS IS A DATA-DRIVEN, RETROSPECTIVE, LONGITUDINAL, POPULATION BASED, OBSERVATIONAL, MULTI-CENTERED STUDY USING SECONDARY DATA CAPTURED FROM CONGRUENT ELECTRONIC HEALTH RECORDS. THE TARGET POPULATION OF INTEREST IN THIS STUDY IS PATHOLOGICALLY DOCUMENTED EARLY BREAST CANCER (BC) OR LOCALLY ADVANCED BC OR DE NOVO METASTATIC BC WITH DOCUMENTED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) AND ESTROGEN RECEPTOR (ER)/PROGESTERONE RECEPTOR (PGR) EXPRESSION STATUS AT THE TIME OF DIAGNOSIS. THE MAIN OBJECTIVE IS TO ASSESS THE PREVALENCE OF HER2 EXPRESSION CHANGE BETWEEN INITIAL DIAGNOSIS VERSUS ANY OF SUBSEQUENT BREAST CANCER RELAPSES.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

ESMO Real World Data and Digital Oncology 2025 publication: https://www.esmorwd.org/article/S2949-8201(24)00085-7/fulltext

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

PHERGAIN SITES

home_fondo_you_barra.jpg
Hospital del Mar (Spain) | Hospital de Sant Joan Despí Moisès Broggi (Spain) | Hospital Universitario Doce de Octubre (Spain) | Hospital Universitario Fundación Alcorcón (Spain) | Hospital Universitari Son Espases (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page